This
press release is posted as a service by Angioplasty.Org
Statement of Boston Scientific CEO Jim Tobin
on FDA Meeting
NATICK, Mass., Feb. 3 -- Boston Scientific Corporation (NYSE: BSX - News) today issued the following statement on a meeting between senior officials of the Company and senior officials of the U.S. Food and Drug Administration (FDA).
"It was a productive meeting. We reviewed with the FDA a path to resolve the issues they have identified, and we committed to working closely with them to ensure they are resolved. We take these issues very seriously and are making progress addressing them. Resolving these issues is our highest priority."
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.
This press release contains forward-looking statements. The Company wishes to caution the reader that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with the regulatory process, competitive product offerings and other factors described in the Company's filings with the Securities and Exchange Commission.
Source: Boston Scientific Corporation
